New drug combo tested for Tough-to-Treat lung cancer
NCT ID NCT06812260
Summary
This study is testing whether adding a new immunotherapy drug called HLX10 to standard chemotherapy helps control advanced small cell lung cancer. It is for Japanese patients who have not yet received any treatment for their extensive-stage cancer. The main goal is to see how well the combination shrinks tumors and how safe it is over 24 weeks.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCLC, EXTENSIVE STAGE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Kansai Medical University Hospital Department of Respiratory Oncology
RECRUITINGHirakata, Osaka, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.